CEO Yu-Hsin Lin Files to Sell $22.5M in ADSs Under 10b5-1 Plan
BLTE has more than doubled off its 52-week low of $60.
Summary
CEO Yu-Hsin Lin plans to sell $22.5M in ADSs under a pre-arranged 10b5-1 plan, following the FDA's Priority Review acceptance.
Key Events · Ownership and Investor Activity · BLTE
-
CEO Files to Sell $22.5M in ADSs
Yu-Hsin Lin, CEO and Chairman, filed a Form 144 to sell 126,800 ADSs with an approximate market value of $22,517,144.
-
Sale Under Pre-Existing 10b5-1 Plan
The sale is pursuant to a 10b5-1 trading plan adopted on December 23, 2025, indicating it was pre-planned and not a discretionary trade.
-
Follows FDA Priority Review Acceptance
The filing comes one day after the FDA accepted the NDA for tinlarebant with Priority Review, which likely contributed to the stock's recent strength.
-
Prior Insider Sale This Week
On the same day, officer/director Hao-Yuan Chuang filed to sell 93,800 ADSs (~$16.7M) under a separate 10b5-1 plan, indicating multiple insiders are monetizing positions.
Analysis · BLTE · Life Sciences
CEO and Chairman Yu-Hsin Lin filed a Form 144 to sell 126,800 American Depositary Shares worth approximately $22.5 million. The sale is under a pre-existing 10b5-1 plan adopted on December 23, 2025. This is a significant insider sale by the top executive, though it is pre-planned and not a discretionary trade. The filing comes one day after the FDA accepted the company's NDA for tinlarebant with Priority Review, which drove the stock price higher.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLTE was trading at $178.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $60.00 to $200.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.